在采用细胞疗法中,利用科病毒衍生抗原对抗病毒恶性瘤
Wei Zhang1,2, Miao Zeng1,2, Yisheng Li3,4
1Department of Hematology and Oncology, Shenzhen University General Hospital, International Cancer Center, Hematology Institution of Shenzhen University, Shenzhen University Medical School, Shenzhen University, Shenzhen, Guangdong, 518000, China.
采用细胞疗法 (ACT) 显示出对抗HPV和EBV等瘤病毒的前景. 使用ACT准病毒coproteins可能会消除病毒驱动的癌症并改善患者的治疗结果.
科学领域:
- 免疫学 免疫学 免疫学
- 在瘤学瘤学.
- 病毒学 病毒学
背景情况:
- 瘤病毒 (HPV,HBV,HCV,EBV) 与12-25%的人类癌症有关.
- 持续的病毒感染会破坏细胞功能,使癌症治疗复杂化.
- 病毒感染在长期癌症治疗期间增加风险.
研究的目的:
- 审查使用采用细胞疗法 (ACT) 针对病毒相关恶性瘤的理由.
- 探索ACT在根除癌症中涉及的冠状病毒方面的潜力.
- 检查当前的临床试验和病毒特异性ACT的治疗进展.
主要方法:
- 对病毒性恶性瘤的ACT进行的临床前和临床研究的文献综述.
- 分析病毒瘤蛋白作为针对患者量身定制的ACT的目标.
- 对病毒特异性ACT的临床试验现状的评估.
主要成果:
- 病毒抗原特异性ACT提供了一种有前途的策略来对抗冠状病毒驱动的癌症.
- 临床前研究表明,ACT有潜力消除冠状病毒.
- 目前正在进行的临床试验正在调查病毒特异性ACT的疗效和影响.
结论:
- ACT代表了癌症免疫治疗的革命性方法,对病毒性恶性瘤具有显著的潜力.
- 向瘤受限,免疫学外来病毒coproteins是一个关键的策略.
- 进一步的研究和临床试验对于在癌症治疗中推进病毒特异性ACT至关重要.
更多相关视频
10:24Automated Cell Enrichment of Cytomegalovirus-specific T cells for Clinical Applications using the Cytokine-capture System
Published on: October 5, 2015
08:52Generation of Multivirus-specific T Cells to Prevent/treat Viral Infections after Allogeneic Hematopoietic Stem Cell Transplant
Published on: May 27, 2011
相关概念视频
Tumor Immunotherapy
Cancer Vaccines
Cancer vaccines come in two categories: preventive (prophylactic) and treatment (active). Preventive vaccines, such as the Human Papillomavirus (HPV) vaccine, protect against viruses that cause certain...
Mechanisms of Retrovirus-induced Cancers
Cytotoxic T Cells-mediated Immune Response
Immunological surveillance is the ability of immune cells to monitor and eliminate infected cells with intracellular pathogens, neoplastically transformed cells, and cells with non-self antigens. Cytotoxic T cells and NK...
Rous Sarcoma Virus (RSV) and Cancer
RSV is a retrovirus that contains two copies of a plus-strand RNA genome. Its genome consists of four main open...
